The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of the booming market for GLP-1s.
Related Posts
Here’s how tariffs could affect the price of goods like shoes and sweaters
A model from AlixPartners shows what items like sweaters and shoes imported from Vietnam could cost under President Donald Trump’s tariff plans.
Target says its holiday sales were better than expected — but its profits weren’t
The big-box retailer’s report indicates that deals and promotional events motivated shoppers.
There’s a popular tech stock washout Monday as Palantir, Nvidia and Rigetti Computing drop
Popular technology stocks tumbled Monday as bond yields rose, dragging down tech-heavy Nasdaq-100 futures.